Limits...
Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.

- Drugs R D (2010)

Bottom Line: Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections.It is currently in phase III development with promising results so far.This review looks at the development history and scientific profile of this drug to date.

View Article: PubMed Central - PubMed

ABSTRACT
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.

Show MeSH

Related in: MedlinePlus

Forecasts
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585687&req=5

Tab3: Forecasts


Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.

- Drugs R D (2010)

Forecasts
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585687&req=5

Tab3: Forecasts
Bottom Line: Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections.It is currently in phase III development with promising results so far.This review looks at the development history and scientific profile of this drug to date.

View Article: PubMed Central - PubMed

ABSTRACT
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.

Show MeSH
Related in: MedlinePlus